\
&
Contact us
\
&
Contact us
Partnership website: https://scar-europe.org/
This partnership aims to structure and support a network of living labs and research infrastructures accelerating the transition towards agroecology throughout Europe. These living labs and research infrastructures will support farmers in understanding and implementing agroecological practices at the scale needed for positive economic, environmental and social impacts. The European Commission chose the livings labs approach because agroecology is territory-bound and more important changes in ecosystems happen slowly so it is important to look at the same area over a longer period of time to determine the effects.
The partnership is supported by the standing committee on agricultural research (SCAR) which has been in existence since the seventies.
Contact
Commission services: Paola Eulalio, Susana Gaona Saez
Partners: SCAR Strategic Working Group on Agroecology (SCAR-AE) - Nicolas Tinois, Benjamin Sanchez, Torsten Rodel Berg
background: Agroecology in this context means understanding ecosystems better and using this knowledge to design more sustainable farming practices and systems.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
pascal.verheye@vlaio.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
